Context Therapeutics Inc. (CNTX)
NASDAQ: CNTX · Real-Time Price · USD
2.510
+0.170 (7.26%)
At close: Apr 28, 2026, 4:00 PM EDT
2.496
-0.014 (-0.57%)
After-hours: Apr 28, 2026, 7:19 PM EDT
Company Description
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors.
The company’s product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Context Therapeutics Inc.
| Country | United States |
| Founded | 2015 |
| IPO Date | Oct 20, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 15 |
| CEO | Martin Lehr |
Contact Details
Address: 2001 Market Street, Suite 3915 Philadelphia, Pennsylvania 19103 United States | |
| Phone | 267 225 7416 |
| Website | contexttherapeutics.com |
Stock Details
| Ticker Symbol | CNTX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $5.00 |
| CIK Code | 0001842952 |
| CUSIP Number | 21077P108 |
| ISIN Number | US21077P1084 |
| Employer ID | 86-3738787 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Martin A. Lehr | Co-Founder, President, Chief Executive Officer and Director |
| Jennifer Minai-Azary | Chief Financial Officer and Treasurer |
| Alex C. Levit Esq., J.D. | Chief Legal Officer and Corporate Secretary |
| Christopher Beck M.B.A. | Senior Vice President of Operations |
| Jeffrey Liebman | Associate Director of Accounting |
| Jennifer Dashnau M.B.A., Ph.D. | Senior Vice President of Technical Operations |
| Dr. Karen Chagin M.D. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2026 | ARS | Filing |
| Apr 28, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2026 | DEF 14A | Other definitive proxy statements |
| Apr 17, 2026 | PRE 14A | Other preliminary proxy statements |
| Apr 2, 2026 | 8-K | Current Report |
| Mar 23, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 23, 2026 | 8-K | Current Report |
| Mar 23, 2026 | 10-K | Annual Report |
| Mar 13, 2026 | 8-K | Current Report |
| Feb 27, 2026 | 8-K | Current Report |